Dr. Saschveen Singh is a tropical infectious disease advisor for MSF. Read more of MSF's recent work on neglected tropical diseases in pediatric populations, and of Dr. Singh's work at MSF.

Viral hepatitis is a significant cause of disease and death globally. Yet powerful new medical tools to combat hepatitis C and E still reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings.

To mark World Hepatitis Day (July 28th) we highlight recent MSF research on making these breakthrough products more widely accessible and simpler to use.

For hepatitis C, where groundbreaking antiviral drugs can cure nearly all patients, MSF is developing comprehensive, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. In some settings programs focus on the specific needs of highly vulnerable populations, such as people living in remote areas, forcibly displaced refugees, or those co-infected with HIV or TB or who inject drugs.

Turning to prevention, MSF is exploring ways to use the Hepatitis E vaccine more effectively in areas where poor sanitation and water quality regularly lead to outbreaks. Studies in a South Sudanese camp for internally displaced people are strengthening evidence for the vaccine’s feasibility, efficacy, safety and community acceptance, especially for pregnant women and their fetuses. Another report analyzes strategies for overcoming barriers to widespread vaccine adoption.